The present study was performed to compare the longterm effects of 24-h ambulatory blood pressure (BP) control with amlodipine versus valsartan on vascular damage in untreated hypertensive patients. Amlodipine and valsartan have benefits on cardiovascular mortality and morbidity in hypertensive patients. Although ambulatory BP is associated with severity of target-organ damage in hypertensive patients, beneficial effects of ambulatory BP control with amlodipine versus valsartan on vascular damage have not been compared. Pulse wave velocity (PWV), intima-media thickness (IMT) of the carotid arteries, urinary albumin excretion (UAE) and 24-h ambulatory BP were determined in 100 untreated hypertensive patients before and 12 months after the start of antihypertensive therapy with amlodipine or valsartan. Amlodipine and valsartan decreased ambulatory BP similarly, but the variability of 24-h and daytime ambulatory systolic BP was significantly reduced by amlodipine but not by valsartan. The reduced variability of ambulatory systolic BP caused by amlodipine significantly contributed to the improvement of PWV, although both drugs decreased PWV similarly. Carotid IMT was unaffected by treatment with either drug. Valsartan significantly decreased UAE independently of its depressor effect, but amlodipine had no effect on UAE. These results suggest that the 24-h control of ambulatory BP with amlodipine had functionally improved the stiffened arteries of hypertensive patients by the end of 12 months of treatment, in part through reducing BP variability, whereas ambulatory BP control with valsartan decreased the arterial stiffness to the same degree as amlodipine without affecting BP variability maybe through some pleiotropic effects.
Introduction
The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) study demonstrated that amlodipine-based therapy has a greater beneficial effect in intensive control of blood pressure (BP) and lowering the risk of myocardial infarction than valsartan-based therapy in hypertensive patients already on antihypertensive drugs. 1 However, the beneficial effects of amlodipine and valsartan on untreated hypertensive patients had never been compared.
Studies have demonstrated that 24-h ambulatory BP predicts cardiovascular morbidity and mortality much more accurately than conventional clinic BP, [2] [3] [4] [5] [6] [7] and that ambulatory BP is better controlled throughout a 24-h period by amlodipine than by valsartan. 8 Thus, it appeared that the intensive control of ambulatory BP by the long-acting nature of amlodipine might have a beneficial effect on the vascular damage of untreated hypertensive patients. Moreover, a recent study reported a greater reduction in the aortic pulse wave velocity (PWV) of hypertensive patients, which predicts cardiovascular morbidity and mortality [9] [10] [11] [12] by long-term treatment with valsartan than with a long-acting calcium channel blocker, even though both drugs decreased the BP similarly. 13 Thus, the pleiotropic effects of valsartan may make an important contribution to improving the arterial stiffness of untreated hypertensive patients.
The aim of this study was to compare the longterm effects of 24-h ambulatory BP control with amlodipine and valsartan on vascular damage in hypertensive patients who had never been treated with any antihypertensive drugs. Renal vascular damage was evaluated by urinary albumin excretion (UAE), and extra-renal vascular damage was func-tionally and structurally assessed on the basis of PWV and the intima-media thickness (IMT) of the carotid arteries.
Materials and methods

Study population and design
The subjects of the present study were 100 consecutive untreated hypertensive patients who attended the outpatient hypertension clinic of Keio University Medical School Hospital and for whom baseline arterial stiffness measurements by PWV were available. Patients with arrhythmias, previous cardiovascular events or peripheral arterial disease were not included in the study. The 24-h ambulatory BP and three times clinic BP were determined during the 3-month observation period before the study. Hypertension was defined as a clinic systolic BP of 4140 mm Hg at any times and/or a clinic diastolic BP of 490 mm Hg at any times and as 24-h ambulatory systolic BP of 4135 mm Hg and/or 24-h ambulatory BP of 480 mm Hg. No patients with any form of secondary hypertension based on the results of classic laboratory and radiology tests were included. All hypertensive patients were randomly assigned to an amlodipine group or a valsartan group. The amlodipine group was started at a dose of 2.5 mg/day, and the dose was subsequently increased by 2.5-mg increments at intervals of 4 weeks. If the target BP of o130/85 mm Hg was not achieved at the maximum dose of 10 mg/day, a b-blocker was added, and then, if necessary, a diuretic was also added. The valsartan group was started at a dose of 40 mg/day, and the dose was subsequently increased in 40-mg increments at intervals of 4 weeks. If the target BP of o130/85 mm Hg was not achieved at the maximum dose of 160 mg/day, a diuretic was added, and then, if necessary, a b-blocker was also added. Clinical and biological parameters were obtained before and 12 months after the start of medication with the antihypertensive drugs. The study was approved by the review board of Keio University Medical School Hospital, and informed consent was obtained from every subject.
Creatinine, uric acid, total cholesterol, triglyceride, high-density lipoprotein, low-density lipoprotein, C-reactive protein, active renin concentrations and superoxide dismutase (SOD) activity, which in the leucocyte correlates with longevity, 14 were measured in venous blood samples drawn in the morning after an overnight fast on the same days as the PWV measurements were made.
Ambulatory BP monitoring
The 24-h ambulatory BP monitoring was performed with an oscillometric-based device (TM-2431; A&D Co., Tokyo, Japan). BP was measured every 30 min during the daytime period (between 0600 and 2200 hours) and every 60 min during the night time period (between 2200 and 0600 hours). Mean values and standard deviations of ambulatory BP for each subject were calculated for 24 h and separately for the daytime and night time periods. The standard deviation of the ambulatory BP values was recorded as the variability of ambulatory BP in this study. The nocturnal decrease in BP was calculated as the average systolic BP during the daytime period minus the average systolic BP during the night time period. The morning BP surge was calculated as the average systolic BP during the first 2 h after waking minus the lowest systolic BP during the night time period.
Pulse wave velocity Clinic BP and PWV were determined with a pulse pressure analyser (model: BP-203RPE, Nihon Colin, Tokyo, Japan) by the methods described previously. [15] [16] [17] [18] Briefly, pulse volume waveforms were recorded with plethymographic sensors placed over the right brachial artery and both posterior tibial arteries. The PWV values measured by this method are significantly correlated with carotid-femoral PWV, 19 heart-ankle PWV 17 and aortic PWV measured by the catheter method, 20 with high correlation coefficients of 0.81, 0.89 and 0.87, respectively. The best 10 consecutive pulses were analysed in the present study, and the average PWV was recorded. The PWV was measured when the patients' heart rate was stable at 60-80 beats/min after at least a 5-min rest. Two measurements were performed in each leg, and the average values were used in the analysis. Values are expressed in units of cm/s.
Carotid IMT
Ultrasonography B-mode imaging of the carotid artery was performed with a PowerVision 6000 machine (Toshiba, Tokyo, Japan) at a transducer frequency of 7.5 MHz. Each subject was examined in the supine position. Up to 4 cm of the common carotid artery and the carotid bulb were scanned bilaterally in the longitudinal and the transverse projections. The image was focused on the far wall of the artery. The IMT was defined as the distance between the leading edge of the lumen-intima interface and the leading edge of the mediaadventitia interface of the far wall, and the greatest IMT value in the bilateral longitudinal projections was recorded as the maximum IMT. All measurements were performed under blind conditions. The mean intraobserver and interobserver coefficients of variation for maximum IMT were 4.3 and 4.7%, respectively.
Urinary albumin excretion UAE was evaluated on the basis of the mean albumin-to-creatinine ratio in three non-consecutive overnight urine samples collected 1 week before 
Results
Patient characteristics
Clinic BP and 24-h ambulatory BP of 100 patients in the present study averaged 15471/9771 and 15071/9371 mm Hg, respectively. Forty-two patients had a mild hypertension defined as a clinic systolic BP of o160 mm Hg and a clinic diastolic BP of o100 mm Hg. Table 1 shows no significant differences in patient characteristics between the amlodipine group and valsartan group in any of these baseline values, and no significant changes were observed in either group during the 12-month observation period. However, as shown in Figure 1 , serum SOD activity significantly increased from 2.970.2 to 3.470.2 U/ml in the valsartan group during the 12-month treatment period, whereas the serum SOD activity of the amlodipine group averaged 3.070.2 U/ml and did not change significantly during the 12-month treatment period. The average doses of amlodipine and valsartan that the patients were taking at the end of the observation period were 7.070.3 and 105.875.5 mg/day, respectively. Prescription of a diuretic was added on for three patients in the amlodipine group and 14 patients in the valsartan group, and the proportion of patients who received a diuretic in the valsartan group was greater than in the amlodipine group (P ¼ 0.003). Prescription of a b-blocker was added on for eight patients in the amlodipine group and four patients in the valsartan group, and the numbers of patients who received a b-blocker in the amlodipine group and valsartan group were similar (P ¼ 0.218). Table 2 shows the changes between clinic BP and 24-h, daytime and night time ambulatory BP in the amlodipine group and valsartan group at baseline and after 12 months of treatment. Clinic systolic/ diastolic BP and 24-h, daytime and night time ambulatory systolic/diastolic BP significantly decreased during the 12-month treatment period in both the amlodipine group and the valsartan group, and the decreases in BP were similar in both groups. However, BP variability assessed on the basis of the standard deviation of 24-h or daytime systolic BP significantly decreased in the amlodipine group, but remained unchanged in the valsartan group. The decrease in BP variability observed in the amlodipine group was statistically significant in comparison with the change in the valsartan group. The BP variability of night time systolic BP and of random diastolic BP in the amlodipine group and valsartan Ambulatory BP and vascular damage A Ichihara et al group was similar. The nocturnal BP decrease and morning BP surge in both the amlodipine group and valsartan group tended to decrease during the 12-month period, but the differences were not significant. The change in nocturnal BP decrease and the change in morning BP surge were both similar in the amlodipine group and valsartan group.
Clinic and ambulatory BP
Target-organ damage
The baseline PWV values in the amlodipine group and valsartan group were similar, averaging 17237 52 and 1671755 cm/s, respectively. Figure 2 shows that PWV significantly decreased to 1517738 cm/s in the amlodipine group and to 1489738 cm/s in the valsartan group, and the decreases in PWV in both groups were also similar. However, 12 months of treatment with amlodipine or valsartan did not alter the maximum IMT of the carotid arteries, which averaged 0.9270.05 and 0.8870.04 mm, respectively, at baseline. UAE in the amlodipine group and valsartan group averaged 33.3711.7 and 40.9710.0 mg/g of creatinine, respectively, and significantly decreased to 18.674.9 mg/g of creatinine with valsartan treatment, but remained unchanged with amlodipine treatment. Table 3 shows that the decreases in clinic systolic BP, clinic diastolic BP, 24-h systolic BP, variability of 24-h systolic BP and variability of daytime systolic BP significantly contributed to the decrease in PWV during the 12-month treatment period, but that other factors of clinic and ambulatory BP did not affect the decrease in PWV (data not shown). In addition, an interactive influence by the drugs was observed in the decrease in PWV owing to the decrease in variability of 24-h systolic BP and in the decrease in PWV owing to the decrease in variability of daytime systolic BP. More specifically, the decreases in variability of 24-h and daytime ambulatory systolic BP caused by amlodipine significantly contributed to the decrease in PWV of the hypertensive patients. Changes in the other clinical and biological parameters, including serum SOD activity, did not contribute to the changes in PWV.
Factors affecting PWV and UAE
The ANCOVA analyses also showed that the decreases in 24-h systolic BP, 24-h diastolic BP, night time systolic BP and night time diastolic BP significantly contributed to the decrease in UAE during the 12-month treatment period, but the other factors of clinical or ambulatory BP had no effect on the decrease in UAE. Although the 12-month treatment with valsartan, but not with amlodipine, significantly decreased UAE, no interactive influence by the drugs was observed in the decrease in UAE owing to the decrease in ambulatory BP. In other words, valsartan treatment decreased UAE independently of its depressor effects. Changes in other clinical and biological parameters, including serum SOD activity, did not contribute to the changes in UAE.
Multiple regression analysis
Multiple regression analysis for five explanatory variables including 24-h (Table 4 , R 2 ¼ 0.190, P ¼ 0.013) or daytime systolic BP parameters (Table 5 , R 2 ¼ 0.168, P ¼ 0.028) indicated significant associations between changes in PWV and changes in 24-h or daytime systolic BP variability, especially in the amlodipine group. Changes in PWV were also asso- 
Discussion
The results of the present study showed that both amlodipine and valsartan significantly decreased clinic BP, 24-h ambulatory BP and PWV, and that the decreases in the amlodipine group and valsartan group were similar. As the decreases in 24-h ambulatory systolic BP significantly contributed to the decrease in PWV in the hypertensive patients treated with either amlodipine or valsartan, the lowering of BP itself may play a more important role in improving arterial stiffness independent of the class of antihypertensive drug used. However, longterm treatment with amlodipine significantly decreased the variability of ambulatory BP, and the reduction contributed to the reduction in PWV. Long-term treatment with valsartan significantly increased serum SOD activity and decreased UAE. The variability of BP is estimated as the standard deviation of non-invasively monitored ambulatory BP, 21 and is associated with the arterial wall stiffness assessed by PWV 22 and the cardiovascular morbidity and mortality of hypertensive patients. 3, 4, 23 These findings suggested two possible cause-effect relationships between BP variability and arterial stiffness, that is, the increase in BP variability may be attributable to the increased stiffness and decreased compliance of the large elastic arteries caused by the elevated BP, 24 or the increased BP variability may be the cause of the increasing stiffness and decreasing compliance of the large elastic arteries. However, as the present study showed that BP lowering with valsartan significantly decreased PWV in the absence of any reduction in BP variability, BP variability may be a causal, but not resultant, factor that affects the stiffness and compliance of the large elastic arteries. Angiotensin II receptor blockers preferentially dilate efferent arterioles, 25 and thereby decrease intraglomerular pressure, which leads to a reduction in proteinuria. As a reduction in proteinuria has been observed at doses of angiotensin II receptor blockers that did not affect systemic BP in a rat model of hypertension, 26 the glomerular protection provided by angiotensin II receptor blockers is thought to be independent of their effects on systemic BP. In the present study, the angiotensin II receptor blocker valsartan decreased UAE, but the calcium channel blocker amlodipine, which produced a similar reduction in BP, did not. Thus, the decrease in UAE with valsartan may not be owing to its depressor effect, but owing to pleiotropic effects independent of its depressor effect. In addition, valsartan has been reported to reduce the formation of reactive oxygen species to a greater extent than amlodipine in monocytes harvested from hypertensive patients, 27 and angiotensin II receptor blockers had a beneficial effect on the arterial stiffness of hemodialysis patients with increased oxidative stress. 17 As valsartan significantly increased serum SOD activity in the present study, we expected the enhanced ability of valsartan to scavenge serumreactive oxygen species to have a beneficial impact on the arterial wall, but the increase in serum SOD activity was not associated with changes in PWV or UAE. A longer observation period may be required to determine the benefit of the antioxidative effects of valsartan.
Previous studies demonstrated that intensive BP lowering in hypertensive patients is associated with a significant decrease in PWV 16 and a lower rate of cardiovascular events. 28 Prescription of amlodipine of 47.5 mg/day was useful in successful long-term BP control with a target BP of o130/85 mm Hg, and the PWV of hypertensive patients receiving amlodipine decreased significantly. 16 However, the reason why the PWV of hypertensive patients receiving short-acting calcium channel blockers failed to decrease, despite a significant decrease in clinic BP, 16 remained unclear. In the present study, amlodipine was found to significantly decrease BP variability and to intensively control BP throughout a 24-h period. As the decrease in BP variability was significantly associated with the decrease in PWV, BP variability may play a key role in the success of calcium channel blockers in decreasing PWV.
Both 12-month treatment with amlodipine and valsartan did not improve IMT. As previous studies demonstrated that calcium antagonist lacidipine slows down the progression of IMT, 29 amlodipine and valsartan might inhibit the progression of IMT rather not influence IMT. Alternatively, IMT reflects structural changes in the wall of the internal carotid artery, although PWV reflects both structural changes in the artery wall and its functional flexibility. Recent studies reported that the functional improvement of arterial endothelium occurred initially after 2 months of treatment with amlodipine 30 and after 6 weeks of treatment with valsartan. 31 The decrease in PWV after 12 months of treatment with amlodipine and valsartan observed in the present study may reflect the improved endothelial function. A longer period of treatment may be needed for IMT to improve.
Multiple regression analyses showed significant correlations between changes in PWV and changes in systolic BP variability, although the coefficients of ANCOVA models including the variability of 24-h ambulatory systolic BP and the variability of daytime systolic BP might not be precise because of interactions. These results suggest that changes in systolic BP variability can impact on arterial wall independently of changes in the mean of 24-h ambulatory systolic BP levels. In addition, there was a significant correlation between changes in PWV and changes in UAE in all patients treated with amlodipine or valsartan. As microalbuminuria may 32 the changes in UAE be accountable for the decrease in PWV in the treated hypertensive patients. However, as none of the independent variables in the multiple regression analyses for the valsartan group are significantly correlated with reductions in PWV, the exact mechanisms involved in valsartan-dependent reductions in PWV remain obscure.
The Conduit Artery Function Evaluation study recently showed that amlodipine-based therapy significantly decreased the central arterial pressure assessed by augmentation index compared to b-blocker-based therapy even if peripheral arterial pressure was similar in both groups. 33 Thus, the decrease in central arterial pressure may contribute to the improvement of cardiovascular risk in hypertensive patients. In the present study, however, augmentation index was not determined. Further study is needed to determine whether there are any differences in the effects of amlodipine and valsartan on central arterial pressure.
Although the numbers of patients who received a b-blocker in the amlodipine group and valsartan group were statistically similar, the proportion of patients who received a diuretic in the valsartan group was significantly greater than in the amlodipine group. In combination with angiotensin II type 1 receptor blockers, therefore, the diuretics use was not only useful in BP reduction but also might contribute to the decreases in PWV and UAE.
In conclusion, both amlodipine and valsartan similarly controlled 24-h ambulatory BP in untreated hypertensive patients and had improved the function of their stiffened arteries by the end of 12 months of treatment. However, valsartan therapy was more effective on microalbuminuria and increased serum SOD activity, although none of the independent variables in the multiple regression analyses for the valsartan group are significantly correlated with reductions in PWV. Some hemodynamic and non-hemodynamic factors can contribute to the progression of arterial stiffness. Although amlodipine and valsartan similarly reduced BP and PWV, beneficial effects of amlodipine therapy on arterial stiffness were mediated mainly through the reduction of BP variability, and those effects of valsartan therapy were mediated possibly through some pleiotropic effects.
What is known about this topic:
K In hypertensive patients already on antihypertensive drugs, amlodipine-based therapy has a greater beneficial effect in intensive control of blood pressure (BP) and lowering the risk of myocardial infarction than valsartan-based therapy.
1 K Ambulatory BP is better-controlled throughout a 24-h period by amlodipine than by valsartan, 8 whereas valsartan exerts a greater reduction in arterial stiffness of hypertensive patients than a long-acting calcium channel blocker. 13 What this study adds:
K In untreated hypertensive patients, both amlodipine and valsartan similarly control 24-h ambulatory BP and improve the function of their stiffened arteries. K Reduction in BP variability plays a significant role in the decrease in arterial stiffness with long-term treatment with amlodipine. K Long-term treatment with valsartan reduces arterial stiffness through some pleiotropic effects, involving the decrease in UAE and increase in serum SOD activity.
Ambulatory BP and vascular damage
